Rationale: Corticotropin-releasing factor (CRF) produces anxiety-like and aversive effects when infused directly into the various regions of the brain, including the bed nucleus of the stria terminalis (BNST). However, the CRF receptor subtypes within the BNST mediating these phenomena have not been established. Objectives: We used selective CRF receptor antagonists to determine the receptor subtypes involved in the anxiogenic-like and aversive effects CRF in the BNST. Materials and methods: Male Long-Evans rats were bilaterally infused with CRF (0.2 or 1.0 nmol) either alone or in combination with the CRF 1 receptor antagonist CP154,526 or the CRF 2 receptor antagonist anti-sauvagine 30 (AS30) before behavioral testing in the elevated plus maze or place conditioning paradigms. Results: Intra-BNST administration of CRF produced a dose-dependent reduction in open arm entries and open arm time in the elevated plus maze, indicating an anxiogenic-like effect. These effects were inhibited by co-infusion of CP154,526 but not of AS30, indicating that the anxiogenic-like effects of CRF in the BNST are mediated by CRF 1 receptors. Place conditioning with intra-BNST administration of CRF produced a dose-dependent aversion to the CRFpaired environment that was prevented by co-infusion of either CP154,526 or AS30, indicating that both CRF receptor subtypes mediate the aversive effects of this peptide. Intra-BNST infusions of the CRF receptor antagonists alone produced no effects in either behavioral paradigm. Conclusions: CRF 1 receptors in the BNST mediate the anxiogenic-like effects of CRF in this region, whereas both CRF 1 and CRF 2 receptor subtypes mediate the conditioned aversive effects of this peptide within the BNST.
Introduction
The extended amygdala, consisting of various limbic and basal forebrain structures including the bed nucleus of the stria terminalis (BNST), is known to mediate behavioral and autonomic responses to stressors, including fear and anxiety (Alheid 2003; Alheid et al. 1995; Davis 1998; Heimer 2003; Schulkin et al. 2005; Walker et al. 2003) . For example, electrical stimulation of the BNST in rats produces behavioral and endocrine changes similar to those evoked by stress (Casada and Dafny 1991; Dunn 1987) , whereas lesions or pharmacological inactivation of the BNST decrease behavioral and endocrine responses to conditioned or unconditioned stressful stimuli (Bangasser et al. 2005; Davis et al. 1997; Fendt et al. 2003; Gewirtz et al. 1998; Gray et al. 1993; Hammack et al. 2004; Henke 1984; Schulz and Canbeyli 1999; Sullivan et al. 2004; Walker and Davis 1997 ; but see Treit et al. 1998) . Lesions of the BNST also enhance learned despair (Schulz and Canbeyli 2000) , and, thus, this brain region may also mediate coping mechanisms in response to uncontrollable stress.
The BNST contains numerous cell bodies that synthesize corticotropin-releasing factor (CRF) (Cummings et al. 1983; Ju et al. 1989; Moga et al. 1989; Morin et al. 1999; Olschowka et al. 1982; Sakanaka et al. 1987; Swanson et al. 1983 ), a 41-amino-acid peptide that mediates anxiety-and stress-like responses (see Bale and Vale 2004, for recent review) . In addition to these CRF-containing cell bodies, the BNST also contains CRF-immunopositive fibers and terminals (Cummings et al. 1983; Morin et al. 1999; Olschowka et al. 1982; Sakanaka et al. 1987; Swanson et al. 1983) , which originate from the central nucleus of the amygdala (Sakanaka et al. 1986) .
Various investigators have shown significant stress-or anxiety-like behavioral and autonomic effects of infusions of CRF into the BNST in rodents. For example, intra-BNST administration of CRF facilitates the acoustic startle reflex , enhances retention of an inhibitory avoidance task (Liang et al. 2001) , and produces anorectic effects (Ciccocioppo et al. 2003) and tachycardia (Nijsen et al. 2001) . Infusions of nonselective CRF antagonists into the BNST conversely produce anxiolyticlike and anti-stress effects, such as attenuated defensive burying behavior (Greenwell et al. 2004) , reduced conditioned freezing and stress-induced cardiovascular abnormalities (Nijsen et al. 2001) , and reduced conditioned defensive-submissive behavior in response to social defeat (Jasnow et al. 2004 ). However, the BNST contains both CRF 1 and CRF 2 receptor subtypes (Chalmers et al. 1995; Chen et al. 2000; Rominger et al. 1998; Rybnikova et al. 2003; Van Pett et al. 2000) , and although CRF has a higher affinity for CRF 1 over CRF 2 receptors (Vaughan et al. 1995) , it is currently unclear which of these two receptors mediates the behavioral effects of CRF in the BNST.
The goal of the present study was to use subtypeselective CRF receptor antagonists to determine which of the two primary CRF receptor subtypes mediate the anxiogenic-like effects of intra-BNST infusion of CRF. In addition, as intracerebroventricular (icv) administration CRF can produce a conditioned place aversion (Cador et al. 1992) , we sought to determine if intra-BNST administration of CRF would also induce a conditioned place aversion and which CRF receptor subtypes might be involved.
Materials and methods

Subjects
All experimental procedures were conducted in accordance with the National Research Council's Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research (2003) and with the approval of an institutional animal care and use committee. Male Long-Evans rats (250-300 g upon arrival, Harlan, Indianapolis, IN, USA) were individually housed in standard polycarbonate cages. The animals were maintained on a 12:12 light-dark cycle (lights on at 0600 hours) with ad libitum access to food and water except during behavioral testing. All experimentation was conducted during the light portion of the lightdark cycle.
Drugs
Synthetic rat/human CRF was obtained from American Peptide Company (Sunnyvale, CA, USA) and was dissolved in artificial cerebrospinal fluid (aCSF, Harvard Apparatus, Holliston, MA, USA). The selective CRF 1 receptor antagonist CP154, 526 (butylethyl[2, 4, pyrimidin-4-yl] amine) hydrochloride (Chen et al. 1997; Seymour et al. 2003 ) was a generous gift from Pfizer (Groton, CT, USA) and was dissolved in sterile water containing 0.1% (v/v) acetic acid before dilution to the appropriate concentration in aCSF. The selective CRF 2 receptor antagonist antisauvagine-30 (AS30; Ruhmann et al. 1998 ) was obtained from Polypeptide Laboratories (Torrance, CA, USA) and dissolved in aCSF.
Surgical procedures
Rats were anesthetized with 5% (v/v) isoflurane vaporized in oxygen at a flow rate of 0.4 l/min and placed into a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA). Anesthesia was maintained throughout the surgery at 1-2% (v/v). An incision was made to expose the skull and rats were bilaterally implanted with microinjection guide cannulae (26 ga OD, Plastics1, Roanoke, VA, USA) aimed to terminate 1 mm dorsal to the BNST (AP −0.26 mm, ML ±1.5, and DV −6.2 mm from bregma and skull surface according to the atlas of Paxinos and Watson (2005) . Guide cannulae were fitted with dummy injectors to prevent obstruction and contamination and were secured to the skull with stainless steel screws and dental cement. The wound was treated with topical bacitracin (2% w/v) and xylocaine (5% w/v) ointments and sutured closed with 4-0 Vicryl sutures. The animals were allowed at least 5 days of recovery in the home cage before subsequent procedures.
Elevated plus maze procedures
After surgical procedures, the animals were randomly assigned to one of the various treatment groups (vehicle, CRF alone, CRF+antagonists, and CRF antagonists alone) for elevated plus maze testing. Before testing, the animals were handled for approximately 5-10 min daily for at least 1 week, during which dummy injectors were removed and immediately replaced to keep the cannulae free of obstruction and to habituate the animals to microinjection handling procedures. On the day of experimentation, the animals were transferred to a darkened testing room containing the elevated plus maze apparatus (approximately 10-20 lx at the center of the maze) and allowed to habituate for at least 1 h before testing. The animals then had their dummy injectors removed and were inserted with clean microinjection needles (33-ga OD) that extended 1 mm beyond the ventral tip of the guide cannulae. Drug solutions containing CRF (0.2 or 1.0 nmol) and/or CP154,526 (0.2 or 1.0 nmol) or AS30 (0.2 or 1.0 nmol) were then infused at a rate of 0.5 μl/min over a period of 1 min while the animal was placed in a 35-cm diameter cylindrical Plexiglas container. After drug infusion, microinjection needles remained in place for an additional 1 min to allow for diffusion of the substances into the surrounding tissue, and then the injector was removed and replaced with the dummy injector. The animals were then returned to the home cage for 5 min. The animals were next placed onto the center of the elevated plus maze apparatus (SciPro, Sanborn, NY, USA) for 10 min while being videotaped. The videotapes were later scored for time spent in the open arms, time spent in the closed arms, and number and open and closed arm entries by one of three investigators blind to the experimental condition. Each investigator was trained to score elevated plus maze videos until inter-observer reliability was >90%. The elevated plus maze apparatus was constructed of white polyvinylchloride plastic and consisted of two open arms (44 cm long × 15 cm wide) bisecting at a 90°angle two closed arms (44 cm long × 14 cm wide with 22.5-cm-high walls). The maze was placed on an aluminum frame so that the arms were elevated 75 cm from the ground. All animals were tested on the elevated plus maze apparatus only once.
Place conditioning procedures
At least 1 week after the elevated plus maze procedures, a randomly chosen subset of animals were selected for place conditioning procedures and assigned to one of the various treatment groups (CRF alone, CRF + antagonists, and CRF antagonists alone). In brief, the rats were placed into a three-compartment place preference apparatus (Med Associates, St. Albans, VT, USA) equipped with two distinct conditioning compartments (28×21×21 cm) that differed in color, lighting, and floor texture, separated by a smaller central neutral gray compartment (12×21×21 cm). Access to one or both of the conditioning compartments was controlled by automatic guillotine-type doors via a remote computer. The position of the animal in the apparatus was determined by computer-interfaced infrared photobeams in each of the three compartments placed 2 cm above the floor at 5 cm apart. During a 30-min pre-conditioning test, rats had access to both conditioning compartments to establish baseline compartment preference. No innate bias towards either of the compartments was observed. Then, over the next 6 days, the animals received alternating infusions of CRF (0.2 or 1.0 nmol) and/or the CRF antagonists CP154,526 or AS30 (0.2 nmol each) or CSF vehicle into the BNST (as described above) and were confined to one of the two conditioning compartments for 20 min. One conditioning session was conducted per day, and the CRF/ drug-paired compartment was counterbalanced across animals. On the day after the last conditioning session, the rats were placed in the center gray compartment and given free access to both conditioning compartments for 30 min to ascertain the development of a conditioned place aversion.
Histology verification of cannulae placement
After experimental procedures, the animals were deeply anesthetized with sodium pentobarbital (150 mg/kg, i.p.) and perfused transcardially with saline followed by 10% formalin. Brains were then removed, immersed in the fixative solution for at least 24 h, and then immersed in a 30% (w/v) sucrose solution for at least 48 h. Brains were then cut into 40-μm coronal sections on a Leica CM1900 cryostat (Leica Microsystems, Bannockburn, IL, USA), mounted onto microscope slides, and stained with cresyl violet for histological verification of cannula and injector placement.
Assessment of CRF diffusion from the injection site
To assess the extent of diffusion of CRF from the tip of the injector, a subset of animals (n=3) received bilateral infusions of CRF that had been labeled with fluorescein isothiocyanate (FITC) using an EZ-Label protein labeling kit (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's directions. The resulting FITClabeled CRF solution was then evaporated under a vacuum and resuspended in aCSF at a concentration of 1.0 nmol/μl. Microinjections of FITC-labeled CRF into the BNST were conducted as described above. Fifteen minutes after the infusion, the rats were deeply anesthetized with sodium pentobarbital (150 mg/kg, i.p.) and perfused transcardially with saline followed by 4% (w/v) paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA). Brains were then removed, immersed in the fixative solution for at least 24 h, and then immersed in a 30% (w/v) sucrose solution for at least 48 h. Brains were then cut into 40-μm coronal sections on a cryostat, mounted onto microscope slides, coverslipped with GelMount mounting media (Biomeda, Foster City, CA, USA) containing an antifade reagent, and viewed under fluorescence (488-nm excitation) using a Leica DMLB microscope equipped with mercury lamp and a digital camera. Data from experiments analyzing the effects of infusions of CRF (with or without co-infusion of specific antagonists) on behavior in the elevated plus maze were analyzed across all treatment conditions by a one-way analysis of variance (ANOVA) followed by Holm-Sidak post hoc multiple comparisons against vehicle-treated animals. Data from experiments analyzing the effects of CRF antagonists alone on behavior in the elevated plus maze were similarly analyzed across all treatment conditions by a one-way analysis of variance followed by Holm-Sidak post hoc multiple comparisons against vehicle-treated animals. When data normality tests failed, a Kruskal-Wallis oneway ANOVA on ranks was performed. In place conditioning experiments examining the effects of intra-BNST infusions of CRF alone, data were analyzed for each dose by one-way repeated measures ANOVA (pre-vs postconditioning) with Holm-Sidak post hoc multiple comparisons. To assess the effects of co-infusion of specific CRF antagonists on place conditioning, post-conditioning data from the high dose of CRF (1.0 nmol) were compared with those of co-infusion with CP154,526 or AS30 by one-way ANOVA with Holm-Sidak post hoc multiple comparisons. p-values less than 0.05 were considered statistically significant for all tests.
Results
Cannula placement
The locations of the tips of the injectors in the BNST for each of the animals with histologically verified correct guide cannulae placement are shown in Fig. 1 (open circles). The location of injector tips from animals that received the 1.0-nmol dose of CRF but were subsequently determined to have erroneous injector placement outside of the BNST are also shown in Fig. 1 (filled circles) . Such brain regions containing erroneously placed injectors included the nucleus accumbens, lateral hypothalamus, and thalamus. This group of animals (n=4) served as a negative anatomical control for the anxiogenic effects of CRF when infused into the BNST.
Diffusion of CRF from the injection site
To assess the extent to which CRF diffuses away from the site of injection, we injected FITC-labeled CRF at a concentration of 1.0 nmol/μl (equal to the highest concentration used in behavioral testing) into the BNST and euthanized the animals 15 min later (equal to the time at which plus maze testing was ended for each subject). As seen in Fig. 2 , the majority of labeled CRF diffused approximately 100-150 μm from the tip of the injector, suggesting that the effects of CRF when injected into the BNST were mediated locally and not by significant diffusion of the peptide into surrounding regions.
CRF subtypes involved in the anxiogenic-like effects of intra-BNST-administered CRF As seen in (n=8) but not of the 0.2 nmol dose of CRF (n=7), compared with vehicle-treated animals (n=6). Total arm entries, an index of general locomotor activity, was not affected by CRF infusion [H(5)=4.79, p>0.05]. Post hoc multiple comparisons revealed that the anxiogenic-like effects of CRF were not observed when guide cannula placement was outside the BNST (i.e., nucleus accumbens, lateral hypothalamus or thalamus, n=4 total) or when CRF was co-infused with the CRF 1 receptor antagonist CP154,526 (1.0 nmol, n=4). However, anxiogenic-like effects were still observed when CRF was coinfused with the CRF 2 receptor antagonist AS30 (1.0 nmol, n=5). Lower (0.2 nmol) doses of CP154,526 or AS30 Locations of the tips of the injectors in animals that were infused with the high (1.0 nmol) dose of CRF but whose injector placement was subsequently shown to be outside of the BNST are shown as filled circles. Numbers to the right of each coronal section represent the distance (mm) of that section from bregma. The diagrams were adapted from the atlas of Paxinos and Watson (2005) (n=5-6 per group) were ineffective at blocking the anxiogenic-like effects of intra-BNST-administered CRF (data not shown).
Effects of intra-BNST administration of CRF receptor antagonists alone on anxiety-like behavior
To determine if CRF subtype-selective antagonists possessed any intrinsic anxiogenic-like or anxiolytic-like activity, we assessed the effects of intra-BNST administration of CP154,526 or AS30 alone on anxiety-like behaviors in the elevated plus maze. Neither the 0.2-nmol (n=6) nor the 1.0-nmol (n=7) dose of the CRF 1 -selective antagonist CP154,526 produced any changes in percent open arm entries [F(2,16)=0.42, p>0.05; Fig. 4a ], percent open time [F(2,16)=1.52, p>0.05; Fig. 4b ], or total arm entries [F (2,16)=1.45, p>0.05; Fig. 4c ] as compared with vehicletreated animals (n=6). Neither the 0.2-nmol (n=8) nor the 1.0-nmol (n=5) dose of CRF 2 -selective antagonist AS30 similarly produced any changes in percent open arm entries [F(2,16)=1.83, p>0.05; Fig. 4d ], percent open time [H(4) =0.71, p>0.05; Fig. 4e ], or total arm entries [F(2,16)=3.50, p>0.05; Fig. 4f ] as compared with vehicle-treated animals (n=6). Co-infusion of either the CRF 1 -selective antagonist CP154,526 (0.2 nmol, n=5) or the CRF 2 -selective antagonist AS30 (0.2 nmol, n=6) with CRF (1.0 nmol) during the conditioning phase prevented the subsequent development of a conditioned place aversion to the CRFpaired compartment [F(1,4)=1.39, p>0.05 for CRF 1.0 + Fig. 2 Assessment of the diffusion of CRF from the tip of the injector. A subset of rats (n=3) used in the behavioral experiments were euthanized 15 min following infusion of FITC-labeled CRF (1.0 nmol/μl) into the BNST. Scale bar=50 μm is given along the x-axis. The CRF 1.0 (nonBNST) group represents animals that received the 1.0-nmol dose of CRF but later were histologically determined to have injector placement outside the BNST. The anxiogenic-like effects of intra-BNST administered CRF (1.0 nmol) were attenuated by co-infusion of the CRF 1 -selective antagonist CP154,526 (1.0 nmol, CRF 1.0 + CP154,426) but not the CRF 2 -selective antagonist AS30 (1 nmol, CRF 1.0 + AS30). No effect of any treatment condition on total arm entries was observed (bottom panel). For CRF treatment, n is six to eight animals per group and for CRF (nonBNST) and CRF + antagonist treatment, n is four to five animals per group. *p<0.05 vs vehicle (CRF 0) group CP154,426; F(1,6)=4.58, p>0.05 for CRF 1.0 + AS30]. When compared with time spent in the CRF (1.0 nmol)-paired compartment after conditioning, co-infusion of either CP154,526 or AS30 along with CRF during conditioning produced a trend toward increasing the time spent in the drug-paired compartment, although these data just missed achieving statistical significance [F(2,13)= 3.61, p=0.06]. The doses of the CRF antagonists employed (0.2 nmol) failed to produce any conditioned place preference or aversion when administered alone into the BNST [F(1,3)=2.42, p>0.05 for CP154,526 (n=4); F(1,2)=0.21, p>0.05 for AS30 (n=3)].
Discussion
We have shown that when administered into the BNST, CRF produces dose-dependent anxiogenic-like effects in rats as measured by the elevated plus maze. These observations are consistent with those of other reports showing increases in stress-like behaviors after intra-BNST infusions of CRF (Ciccocioppo et al. 2003; Lee and Davis 1997; Liang et al. 2001; Nijsen et al. 2001) . Anxiogeniclike effects of CRF were not observed in animals with erroneously placed microinjection needles outside of the BNST in regions such as the lateral hypothalamus, thalamus, and nucleus accumbens, indicating a degree of anatomical specificity for the observed effects of CRF.
Through the use of CRF subtype selective antagonists, we demonstrated that the anxiogenic-like effects of CRF in the BNST are mediated by CRF 1 and not CRF 2 receptors. These findings are consistent with studies showing that the anxiogenic-like effects of CRF are primarily mediated by CRF 1 receptors (Deak et al. 1999; Griebel et al. 1998 Griebel et al. , 2002 Heinrichs et al. 1997a; Schulz et al. 1996; Tezval et al. 2004; Todorovic et al. 2005) and are also consistent with studies in genetically altered mice in which deletion of the CRF 1 receptor gene produces anxiolytic-like effects (Contarino et al. 1999; Muller et al. 2003; Risbrough et al. 2004; Smith et al. 1998; Timpl et al. 1998) . Our data also suggest that the anxiogenic-like effects of centrally (i.e., icv) administered CRF may be mediated, at least in part, by actions within the BNST.
The finding that the anxiogenic-like effects of intra-BNST infusions of CRF were not attenuated by co-infusion of the CRF 2 antagonist AS30, despite the presence of moderate amounts of CRF 2 receptors within the BNST (Chalmers et al. 1995; Chen et al. 2000; Rominger et al. 1998; Rybnikova et al. 2003; Van Pett et al. 2000) , is worthy of discussion. This lack of effect could be attributed to the higher affinity of CRF for CRF 1 over CRF 2 receptors (Vaughan et al. 1995) . However, there is a growing (albeit conflicting) body of evidence that CRF 2 receptors, in addition to CRF 1 receptors, mediate anxiety-like and stress-related behaviors. For example, genetic deletion of the CRF 2 receptor gene in mice has been shown to produce increase in anxiety-like behaviors in the elevated plus maze (Bale et al. 2000; Kishimoto et al. 2000) , although Kishimoto and colleagues demonstrated this effect to be gender specific whereas Bale et al. did not. Others have shown that there is no difference in elevated plus maze behavior between CRF 2 -receptor-deficient mice and wildtype littermates (Coste et al. 2000) . Pharmacological studies on the role of CRF 2 receptors in anxiety-and stress-like responses have yielded equally conflicting results. For example, antagonism of CRF 2 receptors by icv administration of AS30 has been shown to reduce the facilitation of the acoustic startle reflex produced by central administration of CRF (Risbrough et al. 2003) and to produce anxiolytic-like effects in the elevated plus maze (Pelleymounter et al. 2002; Takahashi et al. 2001) , whereas activation of CRF 2 receptors by icv infusions of the endogenous CRF 2 -preferring putative neuropeptide urocortin 2 produce anxiogenic-like effects (Pelleymounter et al. 2002 (Pelleymounter et al. , 2004 . On the other hand, this latter study showed that the anxiogenic-like effects of urocortin 2 were not attenuated by co-infusion of AS30 and also showed that icv administration CRF 2 -preferring ligand urocortin 3 had no effect on behavior in the elevated plus maze (Pelleymounter et al. 2004) , questioning the role of CRF 2 receptors in the behavioral actions of urocortin 2 and 3. Further adding to the confusion of these conflicting reports, some investigators have reported that icv infusions of urocortin 2 or 3 actually produce anxiolytic-like effects in some behavioral paradigms, including the elevated plus maze (Valdez et al. 2002 (Valdez et al. , 2003 (Valdez et al. , 2004 ; but see Venihaki et al. 2004 ) and acoustic startle response (Risbrough et al. 2004) . Thus, there is no current general consensus as to the precise role that CRF 2 receptors play in anxiety-like behaviors and responses to stressors when numerous brain regions are examined at once (i.e., via icv infusions or embryonic gene deletion).
When brain regions are examined individually (i.e., via site-specific microinjections), the role of CRF 2 receptors in governing anxiety-like behaviors becomes slightly more clear. Using a fear conditioning paradigm, Radulovic et al. (1999) demonstrated that infusions of AS30 into the lateral septum but not into the hippocampus facilitated the acquisition of conditioned freezing behavior, suggesting that CRF 2 receptor function in this region has an inhibitory role in conditioned fear responses. Bakshi et al. (2002) subsequently showed that infusions of the dual CRF 1 /CRF 2 receptor antagonist D-Phe-CRF , but not of the selective CRF 1 antagonist NBI27914, actually attenuated unconditioned shock-induced freezing when infused into the lateral septum, suggesting that CRF 2 receptor function in the lateral septum has a permissive role in the expression of unconditioned anxiety-like behavior. It is, therefore, possible that CRF 2 receptors in the lateral septum play a dichotomous role mediating conditioned vs unconditioned anxiety responses. If the same phenomenon were true in the BNST, this may explain, at least in part, why our experiments showed no effects of CRF 2 antagonism on basal or CRF-induced anxiety-like behavior in the elevated plus maze (a measure of unconditioned anxiety-like behavior), whereas CRF 2 receptors in the BNST did appear to mediate the conditioned aversive effects of CRF. This hypothesis is further supported by the recent finding that CRF 2 receptors in the BNST mediate conditioned behavioral responses to social defeat in hamsters (Cooper and Huhman 2005) . Future studies will hopefully further elucidate the role of both CRF 1 and CRF 2 receptor subtypes in the BNST in mediating conditioned vs unconditioned anxiety-like behaviors and responses to stressors.
We were particularly surprised by our current findings that CRF 1 antagonist CP154,526 and the CRF 2 antagonist AS30 produced no anxiolytic-like effects when administered alone into the BNST. These data suggest that neither CRF receptor subtype in the BNST mediates basal levels of anxiety-like behaviors under the current experimental conditions. However, it should be noted that, in our study, the rats that had been well habituated to handling and microinjection procedures were used as subjects to avoid potential floor effects and, hence, an inability to discern any anxiogenic-like effects of CRF (for example, see Andrews and File 1993) . It is, therefore, possible that anxiolytic-like effects of either of these drugs in the BNST might be observed under conditions in which animals have been previously exposed to stress (see, for a review, Hogg 1996) . In support of this possibility, intra-BNST administration of the CRF 2 antagonist AS30 reduces submissivedefensive behaviors induced by conditioned social defeat in the hamster but not in undefeated animals (Cooper and Huhman 2005) . Futher experimentation is needed to address the possibility that blockade of CRF 1 or CRF 2 receptors in the BNST produces anxiolytic-like or antistress effects under different conditions of prior stress exposure.
As with all studies employing exogenous administration of endogenously occurring neuroactive substances into specific brain regions, it is unknown whether the effective concentration of CRF administered (1.0 nmol/μl) in our study is relevant to the extracellular concentrations of this peptide found in the BNST under physiological conditions in either normal or stressed subjects. It is likewise unknown if the extracellular levels of CRF antagonists such as CP154,526 after peripheral administration would reach the concentrations in the BNST achieved by local infusion of 0.2 or 1.0 nmol/μl of these compounds. To our knowledge, no-net flux microdialysis studies estimating the extracellular concentrations of CRF or CRF antagonists in the BNST or other brain regions have not been conducted. Nonetheless, the doses of all infused substances in the present study are comparable to those that have been used by other investigators.
Through the use of FITC-labeled CRF, we demonstrated that the majority of diffusion of CRF is limited to approximately 100-150 μm from the tip of the injector at 15 min post-infusion, and, thus, the anxiogenic-like effects of CRF in the BNST are likely anatomically specific when administered directly into this region. It is possible, however, that conjugation of the FITC molecule (molecular weight ∼390) to CRF (molecular weight ∼4,700) slowed the diffusion of the CRF molecule in comparison with the unlabeled peptide used in our behavioral experiments, resulting in an underestimation of the degree of diffusion of CRF when administered into the BNST. An alternative approach would be to use CRF labeled with a radioactive isotope (i.e., 125 I) as the injected substance, as this modification would likely produce minimal changes in the diffusion characteristics of this peptide. However, this would require the use of autoradiographic techniques to detect the labeled peptide, which generally have lower spatial resolution than fluorescent labeling techniques.
Intra-BNST administration of CRF also produced a dose-dependent conditioned place aversion, paralleling previous findings that icv administration of this peptide produces such an effect (Cador et al. 1992) . Thus, as with CRF-induced anxiety-like behaviors, these data suggest that centrally administered CRF may act within the BNST to produce its aversive effects. It is interesting that we found that co-infusion of either CP154,526 or AS30 blocked the development of a conditioned place aversion to CRF, suggesting that both CRF 1 and CRF 2 receptor subtypes in the BNST mediate the conditioned aversive effects of this peptide, despite CRF displaying a higher intrinsic affinity for CRF 1 over CRF 2 receptors (Vaughan et al. 1995) . As mentioned earlier, this apparent involvement of the CRF 2 receptors in the conditioned aversive effects of intra-BNST administration of CRF, in contrast with the lack of effect of CRF 2 antagonism on the anxiogenic-like effects of CRF in the elevated plus maze (a measure of unconditioned anxiety-like behavior), reveals a potentially dichotomous role of CRF 2 receptors in mediating conditioned vs unconditioned behaviors. For instance, when administered icv, CRF 2 antagonists attenuate CRF-induced potentiation of the acoustic startle reflex (Risbrough et al. 2003 (Risbrough et al. , 2004 . When administered into the lateral septum, CRF 2 receptor antagonism in the lateral septum enhances conditioned freezing (Radulovic et al. 1999 ) but attenuates unconditioned freezing behavior (Bakshi et al. 2002) . Antagonism of CRF 2 receptors in the BNST likewise attenuates conditioned submissive-defensive behaviors in defeated but not in non-defeated hamsters (Cooper and Huhman 2005) . In light of these findings and our current data, it is possible that CRF 2 receptors in the BNST are similarly involved in mediating conditioned vs unconditioned fear-related behaviors.
An alternative explanation for the efficacy of both CRF 1 and CRF 2 antagonists in reversing the conditioned place aversion produced by intra-BNST infusion of CRF is that CRF antagonists may interfere with normal learning and memory processes. For example, CRF has been shown to increase hippocampal long-term potentiation (Blank et al. 2002; Wang et al. 1998 Wang et al. , 2000 and facilitate learning of certain behavioral tasks, including aversive learning (Blank et al. 2002; Garcia-Lecumberri and Ambrosio 2000; Heinrichs et al. 1997b; Hung et al. 1992; Lee 1995; Lee and Sung 1989; Liang et al. 2001; Liang and Lee 1988; Ma et al. 1999; Radulovic et al. 1999; Zorrilla et al. 2002) , while disruption of CRF receptor function can attenuate certain forms of learning (Contarino et al. 1999; Heinrichs 2003) . Thus, the apparent blockade of intra-BNST CRFinduced conditioned place aversion by both CRF 1 and CRF 2 antagonist could be a result of an attenuated ability of the animal to associate the aversive effects of CRF in the BNST with the environment in which CRF is administered, rather than an attenuation of the actual aversive effects of CRF itself. Further studies are needed to dissociate potential learning and memory substrates of CRF receptor antagonists from the aversive properties of CRF in the BNST.
The current findings may have relevance to the neurobiological mechanisms underlying psychiatric disorders such as depression, anxiety, post-traumatic stress disorder (PTSD) and drug addiction. For example, the BNST is activated by acute stressors (Bonaz and Tache 1994; Campeau and Watson 1997; Kollack-Walker et al. 1997; Martinez et al. 1998 Martinez et al. , 2002 , likely from excitatory glutamatergic and/or CRF-containing inputs from the amygdala, ventral subiculum and limbic cortices, and is essential for stress-induced learning (Bangasser et al. 2005) . Chronic stress, which is known to produce depressive-like symptoms such as anhedonia, elevates levels of CRF in the BNST (Chappell et al. 1986; Stout et al. 2000) . In light of the current findings, these elevated levels of CRF in this region may, therefore, contribute to the symptoms of anxiety that often co-occur with depression. In addition, two of the hallmark symptoms of PTSD are anxiety and avoidance of people, objects, or places associated with a severe stressor (American Psychiatric Association 1994), and as the present study demonstrates that intra-BNST administration of CRF induces both anxiogenic-like effects and a conditioned place aversion, these findings may represent a biological substrate of PTSD. Furthermore, we have previously shown using in vivo microdialysis procedures that extracellular levels of CRF are elevated in the BNST during acute alcohol withdrawal and are reduced by subsequent alcohol self-adminstration (Olive et al. 2002) . Taken together with the current findings, it is likely that CRF, acting through CRF 1 receptors within the BNST, contributes to the anxiogenic-like effects of acute alcohol withdrawal, whereas both CRF 1 and CRF 2 receptor contribute to the aversive consequences of this withdrawal state. Finally, other investigators have shown that administration of CRF into the BNST (but not in the central nucleus of the amygdala) reinstates previously extinguished cocaine-seeking behavior (Erb and Stewart 1999) , whereas blockade of CRF receptors in this region (but not in the central nucleus of the amygdala or nucleus accumbens) attenuates the ability of stress to reinstate previously extinguished cocaine-seeking behavior (Erb et al. 2001; Erb and Stewart 1999) or morphine-conditioned place preference (Wang et al. 2006) . Thus, CRF in the BNST appears to contribute to the reinstatement of drugseeking behavior as well withdrawal-induced anxiety-like behaviors.
In conclusion, our results show that in the BNST, CRF acts primarily on CRF 1 receptors to produce anxiety-like behaviors. However, the conditioned aversive effects of CRF in the BNST appear to be mediated by both CRF 1 and CRF 2 receptor subtypes. These results provide neuroanatomical and neurochemical substrates by which CRF produces anxiogenic-like and aversive effects, and this knowledge will hopefully lead to improved therapeutic strategies for the treatment of various psychiatric conditions that involve excessive CRF signaling, such as anxiety, depression, PTSD, alcohol withdrawal, and relapse to drug addiction.
